Financial Information of Accretion Pharmaceuticals Limited IPO
The Revenues from operations for the period ended on Dec 31, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 3,574.93 Lakh, ₹ 3,393.86 Lakh, ₹ 2,953.15 Lakh and ₹ 2,258.42 Lakh respectively. The EBITDA for the period ended on Dec 31, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 882.45 Lakh, ₹ 776.28 Lakh, ₹ 213.85 Lakh, and ₹ 193.10 Lakh, respectively. The Profit after Tax for the period ended on Dec 31, 2024, Fiscals ended 2024, 2023 and 2022 were ₹ 523.55 Lakh, ₹ 387.53 Lakh, ₹ 10.39 Lakh, and ₹ 7.90 Lakh respectively. This indicates a steady growth in financial performance.
| Period Ended | Dec 31, 2024 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 |
|---|---|---|---|---|
| Reserve of Surplus | 541.31 | 134.76 | - | - |
| Total Assets | 3,998.83 | 2,704.61 | 2,059.97 | 1,774.12 |
| Total Borrowings | 1,378.98 | 1,348.22 | 846.58 | 760.75 |
| Fixed Assets | 614.09 | 527.27 | 601.23 | 583.59 |
| Cash | 18.64 | 9.16 | 3.64 | 37.45 |
| Net Borrowing | 1,360.34 | 1,339.06 | 842.94 | 723.30 |
| Revenue | 3,574.93 | 3,393.86 | 2,953.15 | 2,258.42 |
| EBITDA | 882.45 | 776.28 | 213.85 | 193.10 |
| PAT | 523.55 | 387.53 | 10.39 | 7.90 |
| EPS | 8.74 | 9.69 | 0.26 | 0.20 |
Note 1:- RoE, ROCE & RoNW calculation in KPI is based on 31st Mar, 2024 Data, given in RHP.
Note 2:- Pre EPS and Post EPS calculation in KPI is based (Profit/Loss for the Year) on 31st Mar, 2024 Data, given in RHP.
Note 3:- RoNW calculation in KPI is based on 31st Mar, 2024 Data, given in RHP.
Note 4:- Price to Book Value calculation in KPI is based on 31st Dec, 2024 Data, given in RHP.
Copyright @2020 Design & Developed by Info Web Software